Osteologix IND for NB S101 for Osteoporosis Accepted by FDA (Business Wire via Yahoo! Finance)
SAN FRANCISCO—-Osteologix, Inc. , a specialty biopharmaceutical company, today announced that the U. S. Food and Drug Administration has accepted its Investigational New Drug application for its lead development candidate NB S101 , for the treatment and prevention of osteoporosis.